Lei Jianping on May 2
Bloomage Biotechnology Co., Ltd. (stock code: 688363, stock abbreviation: Bloomage Biotech) released its financial report today, which shows that Bloomage Biotech's revenue in the first quarter of 2024 was 1.36 billion yuan, a year-on-year increase of 4.24%.
The government subsidy included in Bloomage Biotech in the first quarter of 2024 is 11.03 million yuan.
Bloomage Biotech's net profit in the first quarter of 2024 was 243 million yuan, a year-on-year increase of 21.39%, and the net profit after deducting non-profits was 231 million yuan, a year-on-year increase of 53.3%.
Hong Kong Securities Clearing Company Limited increased its holdings
As of March 31, 2024, Bloomage Xinyu Investment Co., Ltd. held 58.86% of the shares, China Life Chengda (Shanghai) Health Industry Equity Investment Center (Limited Partnership) held 7.15% of the shares, China Merchants Bank Co., Ltd. - ChinaAMC SSE Science and Technology Innovation Board 50 Component Exchange-traded Open-ended Index Securities Investment Fund held 2.72% of the shares, and Hong Kong Securities Clearing Co., Ltd. held 1.45% of the shares;
As of March 31, 2024, Bloomage Biotech's shareholding structure
Industrial and Commercial Bank of China Co., Ltd.-E Fund SSE STAR Market 50 Component Exchange-traded Open-ended Index Securities Investment Fund holds 1.28% of the shares, Beijing Tonghui Taihe Investment Management Co., Ltd. - Beijing Guoshou Taihe Phase I Equity Investment Partnership (Limited Partnership) holds 1.21% of the shares, WESTSUPREMELIMITED holds 0.99% of the shares, and Tianjin Huajie Haihe Medical Investment Partnership (Limited Partnership) holds 0.84% of the shares;
Bloomage Biotechnology Co., Ltd. holds 0.63% of the shares in the repurchase special securities account, and Bank of China Co., Ltd. - China Merchants Guocheng Biomedical Index Graded Securities Investment Fund holds 0.55% of the shares.
As of December 31, 2023, Huaxi Xinyu Investment Co., Ltd. held 58.86% of the shares, China Life Chengda (Shanghai) Health Industry Equity Investment Center (Limited Partnership) held 7.15% of the shares, China Merchants Bank Co., Ltd. - ChinaAMC SSE Science and Technology Innovation Board 50 Component Exchange-traded Open-ended Index Securities Investment Fund held 2.98% of the shares, and Hong Kong Securities Clearing Co., Ltd. held 1.24% of the shares;
As of December 31, 2023, Bloomage Biotech's shareholding structure
Beijing Tonghui Taihe Investment Management Co., Ltd. - Beijing Guoshou Taihe Phase I Equity Investment Partnership (Limited Partnership) holds 1.21% of the shares, WESTSUPREME Limited holds 0.99% of the shares, Industrial and Commercial Bank of China Co., Ltd. - E Fund SSE Science and Technology Innovation Board 50 Component Exchange-traded Open-ended Index Securities Investment Fund holds 0.88% of the shares, and Tianjin Huajie Haihe Medical Investment Partnership (Limited Partnership) holds 0.84% of the shares;
Fortune Ace Investment Limited holds 0.62% of the shares, and Arrows (Tianjin) Medical Investment Partnership (Limited Partnership) holds 0.53%.
The comparison shows that in the first quarter of 2024, Hong Kong Securities Clearing Co., Ltd. increased its holdings.
———————————————
Lei Di was founded by Lei Jianping, a media person, if it is reprinted, please indicate the source.